Wall Street is casting a brighter spotlight on Gossamer Bio (NASDAQ:GOSS) this week after Barclays stepped out with a “Strong Buy” upgrade, a move that suggests a serious shift in sentiment for the clinical-stage biopharmaceutical player. While the broader analyst community remains a bit more ca utious—landing on a “Moderate Buy” consensus with five Buys and […] Gossamer Bio (NASDAQ:GOSS): The High-Stakes Gamble Drawing Big Bank Interest ...read more read less